Guideline Recommendations

Guideline	Recommendation
NCCN Kidney Cancer v2.2026	Percutaneous ablation (cryoablation, RFA, MWA) as a category 2A option for cT1a (≤4 cm) tumors; category 2B for select cT1b (4.1–7 cm) not eligible for surgery. Biopsy recommended prior to or at the time of ablation. May require retreatment to achieve equivalent local oncologic outcomes to surgery.^[1]
AUA 2021	Thermal ablation is a reasonable alternative for tumors <3 cm. Percutaneous approach preferred over laparoscopic — shorter procedure time, quicker recovery, lower narcotic requirements.^[2]
SIR Position Statement	Ablation offers similar cancer-specific survival with fewer complications compared to partial nephrectomy for T1a RCC. Lower perioperative complication rate: 12.5% vs. 17.0% for PN. Advocates inclusion in multidisciplinary treatment discussions.^[5]

Indications and Contraindications

Indication	Notes
cT1a renal cell carcinoma (≤4 cm)	Primary indication; strongest evidence for ≤3 cm; outcomes comparable to partial nephrectomy
Solitary kidney or CKD	Nephron-sparing priority; eGFR decline 4.47 vs. 13.09 mL/min/1.73 m² after ablation vs. PN^[24]
Hereditary syndromes	VHL, Birt-Hogg-Dubé, HLRCC — multiple tumors expected; serial ablations preserve function
Bilateral or multifocal tumors	Staged ablation preferred over bilateral surgery
Unfit for or declining surgery	Frailty, cardiopulmonary comorbidity; ablation under moderate sedation feasible
Select cT1b (4.1–7 cm)	Expanding indication; cryoablation achieves 95% primary efficacy; ice-ball margin ≥8 mm critical for local control^[20]

Type	Contraindication
Absolute	Uncorrectable coagulopathy · Active untreated infection · Metastatic disease with short life expectancy
Relative	Tumor >4 cm (higher residual risk) · Central/hilar location near collecting system (requires pyeloperfusion) · Adjacent bowel <1 cm (requires hydrodissection) · Upper-pole proximity to pleura (pneumothorax risk)

Ablation vs. Partial Nephrectomy: Oncologic Outcomes

Study	n	Key Finding
Danish nationwide registry (Radiology 2026)^[4]	1,862	No significant difference in progression risk vs. surgical resection for T1a RCC (HR 1.46; 95% CI 0.60–3.56; p=0.40). Local recurrence slightly higher after ablation (2.41% vs. 1.20%; p=0.007) but treatable. Distant metastasis more frequent after nephrectomy (4.38% vs. 1.67%; p=0.02). Median hospital stay 0 days for ablation vs. 2 days.
Propensity-matched analysis (Urology 2025)^[6]	12,546	Comparable 10-year survival: PN 89.4%, cryoablation 89.2%, heat-based ablation 87.8% (p>0.05). Higher reintervention rates at 10 years for ablation (cryoablation 13.0%, heat-based 9.6% vs. PN 1.3%).
Mayo Clinic series (Eur Urol 2019)^[7]	1,798	No significant differences in local recurrence, metastases, or RCC death for cT1a. 5-year CSS: PN 99%, RFA 96%, cryoablation 100%. cT1b: differences in RCC-related death could not be excluded.
Meta-analysis of comparative trials (Front Oncol 2023)^[8]	2,107	Significantly less eGFR decline after ablation (WMD −9.84 mL/min/1.73 m²; p<0.05). Ablation had lower procedural morbidity but higher reintervention rates.

Modality Comparison

Local Control by Modality — Lancet Oncology Meta-Analysis (2025)^[9]

133 studies, n=8,910 patients — most comprehensive comparison of all ablative modalities:

Modality	1-yr Local Control	2-yr Local Control	5-yr Local Control	Grade 3–4 AEs
SBRT	99% (97–100)	97% (95–99)	95% (89–98)	2%
RFA	96% (94–98)	95% (92–98)	92% (88–96)	2%
MWA	97% (95–99)	95% (92–98)	86% (75–94)	1%
Cryoablation	95% (93–96)	94% (91–96)	90% (87–93)	3%

Head-to-Head Modality Data

Comparison	Key Findings
MWA vs. RFA^[10][11]	Meta-analysis (10 studies, n=2,258): MWA had fewer local recurrences than RFA/cryoablation (OR 0.31; p=0.0008) and fewer overall complications than RFA (OR 0.60; p=0.04) and cryoablation (OR 0.49; p=0.01). Single-center series (n=531): MWA superior TRIFECTA achievement (84.2% vs. 72.2%; p=0.001) and shorter operative time.
MWA vs. Cryoablation^[12][13]	12-year single-center study (n=279): no significant differences in local recurrence, cancer-free survival, or overall survival after propensity matching. MWA had significantly shorter ablation time (WMD −24.6 min).
Cryo advantage for 3–4 cm tumors^[14]	DeGIR registry (n=1,102): heat-based ablation had lower technical success (89.8% vs. 96.1%; p=0.005) and higher complication rates (11.1% vs. 3.9%; p=0.002) for 3–4 cm lesions. Cryoablation showed no size-dependent differences in this range.
Cryo advantage for central/hilar tumors^[15]	Slower ice-ball formation allows real-time monitoring and reduces risk of collecting system injury. Preferred modality when collecting system is <4 mm from tumor margin.

Feature	Cryoablation	RFA	MWA
Mechanism	Ice-ball (Joule–Thomson); freeze–thaw cycles	Resistive heating via alternating current	Dielectric heating via EM field
Visible ablation zone	Yes — ice-ball visible on CT/MRI/US	No direct zone; gas/cavitation artifact	Limited; gas artifact
Heat-sink effect	Minimal	Significant near large vessels	Less than RFA
Ablation time	2 × 10 min freeze with 8 min thaw	10–20 min per cycle	2–10 min
Best application	Central, complex, larger tumors; 3–4 cm range	Small peripheral tumors; mature evidence base	Peripheral tumors; near large vessels; lowest complication rate
Grade 3–4 AEs (Lancet Onc)^[9]	3%	2%	1%

Long-Term Cryoablation Outcomes

Cryoablation has the most mature long-term data among ablation modalities:

Study	n / Follow-up	Key Outcomes
Bhagavatula et al. (Radiology 2020)^[16]	307 pts; median f/u 95 months	15-year disease-specific survival 99%; local PFS 95%; overall survival 76%. Primary efficacy 96%, secondary efficacy 99%.
Morkos et al. (Radiology 2020) — 10-year prospective^[17]	134 pts; 10-year prospective	DSS 94% at 5 and 10 years — equivalent to matched PN and RN cohorts from NCDB. 10-year risk of hemodialysis: 2.3%.
Breen et al. (Radiology 2018) — biopsy-proven RCC^[18]	220 pts; biopsy-proven	5-year local recurrence-free survival 93.9%; metastasis-free survival 94.4%; major complication rate 4.9%.

T1b Tumors (4.1–7 cm): Expanding Indications

Ablation of T1b tumors remains more challenging, with higher local recurrence but acceptable outcomes in select patients:

Matched-pair analysis vs. robotic PN (AblatT1b, Eur Radiol 2023):^[19] local recurrence higher after ablation (14.6% vs. 4%; p=0.02) but major complications higher after surgery (5.3% vs. 0%).
Cryoablation for T1b (JVIR 2025, n=80):^[20] primary efficacy 95%, secondary efficacy 98.8%, 24-month local tumor progression-free survival 98.8%. Ice-ball margin ≥8 mm was critical — patients achieving this margin had 100% local control vs. 57% at 6 months for margins <8 mm.
Tertiary center series (CVIR 2026, n=51):^[21] cryoablation ± embolization — 5-year local recurrence-free survival 87%, metastasis-free survival 96%, local recurrence rate 4%.

Tumor Size and Location: Predictors of Success

Optimal size threshold: ≤3 cm. A study of 432 patients identified 3.2 cm as the optimal cutoff for TRIFECTA achievement. Risk of failure increases for tumors >4 cm (OR 1.49).^[22]
Exophytic location is a strong independent predictor of complete necrosis regardless of size. All exophytic tumors achieved complete necrosis in one series.^[23]
Central/hilar tumors carry higher risk of collecting system injury with heat-based modalities; cryoablation with pyeloperfusion preferred. Both small size and exophytic location independently predict success.^[15][23]

Renal Function Preservation

Ablation consistently demonstrates superior renal function preservation compared to surgery — particularly important for solitary kidneys, baseline CKD, and bilateral tumors:^[8][24][25]

Treatment	eGFR Decline
Percutaneous ablation	−4.47 mL/min/1.73 m²
Microwave ablation (large MWA series, n=708)	−5.2% at 6 months
Partial nephrectomy	−13.09 mL/min/1.73 m² / −4.7% at 6 months
Radical nephrectomy	−32.9% at 6 months

Pre-Procedure Imaging and RENAL Score

Multiphase CT or MRI characterizes enhancement, size, laterality, polar location, exophytic fraction, and proximity to the collecting system. The RENAL nephrometry score stratifies tumor complexity:

Component	Points
R — radius (max diameter)	≤4 cm = 1; 4–7 cm = 2; >7 cm = 3
E — exophytic/endophytic	≥50% exophytic = 1; <50% = 2; entirely endophytic = 3
N — nearness to collecting system/sinus	≥7 mm = 1; >4 to <7 mm = 2; ≤4 mm = 3
A — anterior/posterior	Descriptor only (suffix a/p/x)
L — location relative to polar lines	Entirely above/below = 1; crosses polar line = 2; >50% across or between = 3

Low (4–6): favorable for any modality; outpatient
Intermediate (7–9): cryoablation often favored; may need pyeloperfusion
High (10–12): complex; cryoablation with pyeloperfusion; multidisciplinary review

Procedure Overview

The following is a high-level summary. Full probe placement templates, ice-ball size tables by probe type, pyeloperfusion flow rates, and sedation protocols are available in RadCall Pro.

Pre-Procedure

Pre-procedure imaging: CT/MRI with contrast; calculate RENAL score; plan probe trajectory and protective maneuvers.
Biopsy: core biopsy at the start of the ablation session (or prior) for histology — ablated tissue cannot be re-evaluated.
Anesthesia: moderate sedation for cryoablation (less procedural pain); general anesthesia for RFA or centrally located tumors.
Patient position: prone or oblique depending on tumor location; CT guidance is standard.

Pre-cryoablation renal mass stained with lipiodol — Pre-cryoablation renal mass with lipiodol tumor staining to define margins for probe placement.

Pre-ablation angiogram showing renal mass lipiodol staining — Pre-ablation angiogram demonstrating lipiodol tumor staining — selective injection used to mark tumor vascularity and guide probe targeting.

Protective Maneuvers

Hydrodissection: 5% dextrose (D5W — avoid saline for RFA; conductive) instilled to displace adjacent colon, duodenum, or psoas.
Pyeloperfusion: retrograde ureteral catheter placed pre-procedure; cooled D5W infused during ablation to protect urothelium for central tumors abutting the collecting system.
CO₂ or balloon displacement: rarely used to separate from diaphragm or adjacent structures.

Ablation

Probe placement under CT guidance: typically 1–6 probes for conformal ice-ball; avoid interlobar vessels and pelvicalyceal injury on trajectory.
Cryoablation cycle: 10 min freeze → 8 min passive thaw → 10 min freeze (two-cycle standard). Intermittent CT confirms ice-ball growth and margin. Target 5–10 mm ice-ball margin beyond tumor edge (cytotoxic −20°C to −40°C isotherm is several mm inside the visible edge).
RFA/MWA: energy delivered per manufacturer protocol; monitor temperature at margin; overlapping zones for larger tumors.

Immediate post-ablation CT: non-contrast and contrast-enhanced to confirm hypoenhancing ablation zone encompassing tumor plus margin; exclude active hemorrhage.

Post-Ablation Imaging Surveillance

Contrast-enhanced CT or MRI at 1, 3, 6, 12 months, then annually:

Finding	Expected	Concerning for Residual/Recurrent Disease
Ablation zone size	Initially larger than tumor (halo); gradual involution over 1–2 years	Re-growth on serial imaging
Enhancement	Non-enhancing (≤10–20 HU on CT)	Any nodular enhancement or >20 HU at margin
Rim enhancement	Thin smooth peripheral rim in first 3–6 months (reactive)	Thick, nodular, or progressive rim
Perinephric fat	Stranding, fluid collection acutely	Mass effect, soft-tissue nodule

Follow-up MRI showing no enhancement after renal mass cryoablation — Follow-up MRI demonstrating no residual enhancement within the ablation zone after renal mass cryoablation — consistent with complete ablation and treatment success.

Complications

Overall complication rates are low — 8–14% overall, 2–5% major — and significantly lower than partial nephrectomy (SIR: 12.5% vs. 17.0%).^[5][26]

Complication	Rate	Management
Perinephric hematoma	5–15% (most self-limited)	Observation; transfusion or embolization rarely required
Clinically significant hemorrhage	2–4%	Selective angioembolization
Urothelial injury / urine leak / urinoma	0–4%	Ureteral stenting; pyeloperfusion prevents
UTI	~2%	Antibiotics
Pneumothorax (upper-pole tumors)	1–5%	Observation or catheter drainage
Bowel injury	<1%	Hydrodissection prevents; surgical repair if occurs
Ureteral stricture	<1%	Central tumors; pyeloperfusion protective
Tract seeding	Very rare	Track ablation on probe withdrawal

Evidence Summary

Ahrenfeldt J et al (Radiology 2026) — Danish registry, n=1,862: no significant difference in progression risk between ablation and surgery for T1a RCC (HR 1.46; p=0.40); distant metastasis more frequent after nephrectomy (4.38% vs. 1.67%); hospital stay 0 days (ablation) vs. 2 days.^[4]
Huang RS et al (Lancet Oncology 2025) — 133 studies, n=8,910: comprehensive modality comparison; SBRT highest 5-yr control (95%); RFA 92%; cryo 90%; MWA 86%; Grade 3–4 AEs lowest with MWA (1%).^[9]
Stamper M et al (Urology 2025) — propensity-matched, n=12,546: comparable 10-year survival across PN, cryoablation, heat-based ablation (all ~87–89%; p>0.05); higher reintervention rates for ablation.^[6]
Castellana R et al (Eur J Radiol 2023) — MWA vs. RFA/cryo meta-analysis, n=2,258: MWA fewest local recurrences (OR 0.31; p=0.0008), fewest complications.^[10]
Bhagavatula SK et al (Radiology 2020) — cryo long-term, n=307: 15-yr DSS 99%, local PFS 95%; primary efficacy 96%, secondary 99%.^[16]
Morkos J et al (Radiology 2020) — 10-yr prospective cryo, n=134: DSS 94% at 5 and 10 years; 10-yr hemodialysis risk 2.3%.^[17]
Andrews JR et al (Eur Urol 2019) — Mayo Clinic, n=1,798: no significant differences in local recurrence, metastases, or RCC death for T1a; 5-yr CSS cryo 100%, RFA 96%, PN 99%.^[7]
Schaarschmidt BM et al (Eur Radiol 2025) — DeGIR registry, n=1,102: heat-based ablation lower success (89.8% vs. 96.1%) and higher complications (11.1% vs. 3.9%) for 3–4 cm lesions; cryoablation size-independent.^[14]

References

Kidney Cancer. National Comprehensive Cancer Network. Updated 2026-04-14. Version 2.2026.
Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021;206(2):199–208.
Roadman DF, Shapiro DD, Das A, et al. Percutaneous Microwave Ablation Preserves Renal Function With Similar Long Term Oncologic Outcomes Compared to Surgery for Clinical T1 RCC. Cancers. 2026;18(2):334.
Ahrenfeldt J, Jespersen J, Tonnesen P, et al. Ablation and Surgery Show Comparable Long-Term Outcomes for T1a Renal Cell Carcinoma: A Danish Nationwide Registry Study. Radiology. 2026;318(3):e251485.
Morris CS, Baerlocher MO, Dariushnia SR, et al. SIR Position Statement on the Role of Percutaneous Ablation in Renal Cell Carcinoma. J Vasc Interv Radiol. 2020;31(2):189–194.
Stamper M, Collins J, Arellano R, et al. Long-Term Outcomes of Partial Nephrectomy Versus Percutaneous Ablation for RCC: A Propensity-Matched Analysis. Urology. 2025. doi:10.1016/j.urology.2025.07.065.
Andrews JR, Atwell T, Schmit G, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol. 2019;76(2):244–251.
Wen Z, Wang L, Huang J, et al. Perioperative, Functional, and Oncologic Outcomes After Ablation or Partial Nephrectomy for Solitary Renal Tumors: Systematic Review and Meta-Analysis. Front Oncol. 2023;13:1202587.
Huang RS, Chow R, Benour A, et al. Comparative Efficacy and Safety of Ablative Therapies in Primary Localised Renal Cell Carcinoma. Lancet Oncol. 2025;26(3):387–398.
Castellana R, Natrella M, Fanelli G, et al. Efficacy and Safety of MWA Versus RFA and CA for Renal Tumors: Systematic Review and Meta-Analysis. Eur J Radiol. 2023;165:110943.
Jannello LMI, Orsi F, Luzzago S, et al. Microwave vs Radiofrequency Ablation for Small Renal Masses. BJU Int. 2025;135(1):156–165.
Sun G, Eisenbrey JR, Smolock AR, et al. Percutaneous Microwave Ablation Versus Cryoablation for Small Renal Masses ≤4 Cm: 12-Year Experience. J Vasc Interv Radiol. 2024;35(6):865–873.
McClure T, Lansing A, Ferko N, et al. A Comparison of Microwave Ablation and Cryoablation for RCC: Systematic Review and Meta-Analysis. Urology. 2023;180:1–8.
Schaarschmidt BM, Zensen S, Kesch C, et al. Current Use of Percutaneous Ablation in Renal Tumors: Analysis of the DeGIR Registry. Eur Radiol. 2025;35(3):1723–1731.
Krieger JR, Lee FT, McCormick T, et al. Microwave Ablation of Renal Cell Carcinoma. J Endourol. 2021;35(S2):S33–S37.
Bhagavatula SK, Tuncali K, Shyn PB, et al. Percutaneous CT- and MRI-Guided Cryoablation of cT1 RCC: Intermediate- to Long-Term Outcomes in 307 Patients. Radiology. 2020;296(3):687–695.
Morkos J, Porosnicu Rodriguez KA, Zhou A, et al. Percutaneous Cryoablation for Stage 1 RCC: Outcomes From a 10-Year Prospective Study. Radiology. 2020;296(2):452–459.
Breen DJ, King AJ, Patel N, Lockyer R, Hayes M. Image-Guided Cryoablation for Sporadic RCC: 3- and 5-Year Outcomes in 220 Biopsy-Proven Patients. Radiology. 2018;289(2):554–561.
Cazalas G, Klein C, Piana G, et al. Multicenter Comparative Matched-Pair Analysis of Percutaneous Ablation and Robotic PN for T1b RCC (AblatT1b). Eur Radiol. 2023;33(9):6513–6521.
Michailidis A, Kosmoliaptsis P, Makri D, et al. Percutaneous Cryoablation of T1b Renal Tumors: Local Control, Renal Function, and Ablation Margins in 80 Patients. J Vasc Interv Radiol. 2025. doi:10.1016/j.jvir.2025.09.025.
Abdelsalam ME, Awad A, Kang F, et al. Percutaneous Cryoablation of Clinical T1b Renal Tumors: A Tertiary Cancer Center Experience. Cardiovasc Intervent Radiol. 2026. doi:10.1007/s00270-026-04381-y.
Luzzago S, Mistretta FA, Mauri G, et al. Thermal Ablation for Small Renal Masses: Identifying the Most Appropriate Tumor Size Cut-Off. Urol Oncol. 2022;40(12):537.e1–537.e9.
Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency Ablation of RCC: Part 1, Indications, Results, and Role Over 6-Year Period and 100 Tumors. AJR. 2005;185(1):64–71.
Rivero JR, De La Cerda J, Wang H, et al. Partial Nephrectomy Versus Thermal Ablation for cT1 Renal Masses: Systematic Review and Meta-Analysis of >3,900 Patients. J Vasc Interv Radiol. 2018;29(1):18–29.
Yang Q, Meng F, Li K, et al. Safety and Efficacy of Thermal Ablation for Small Renal Masses in Solitary Kidney: Meta-Analysis of Comparative Studies. PLoS One. 2015;10(6):e0131290.
Rose TL, Kim WY. Renal Cell Carcinoma: A Review. JAMA. 2024;332(12):1001–1010.
Related IR guides: HCC percutaneous ablation, CT-guided renal biopsy, renal incidental mass workup.

Full technique in RadCall Pro Probe placement templates by tumor size and geometry, ice-ball tables by probe type, pyeloperfusion flow rates, modality selection algorithm by RENAL score, and sedation protocols available in RadCall Pro.

Start free trial ›

Percutaneous Renal Tumor Ablation — Cryo, RFA, and Microwave